FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion
Published inInternational Journal of Cardiology, vol. 202, p. 52-58
Publication date2016
Abstract
Keywords
- Administration, Oral
- Adult
- Biomarkers, Pharmacological/metabolism
- Dose-Response Relationship, Drug
- Drug Tolerance
- Endothelin Receptor Antagonists/administration & dosage/pharmacokinetics
- Familial Primary Pulmonary Hypertension/drug therapy/metabolism/mortality
- Female
- Follow-Up Studies
- Global Health
- Humans
- Male
- Sulfonamides/administration & dosage/pharmacokinetics
- Survival Rate/trends
- Time Factors
- Treatment Outcome
Research group
Citation (ISO format)
BERGER, Rolf M F et al. FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion. In: International Journal of Cardiology, 2016, vol. 202, p. 52–58. doi: 10.1016/j.ijcard.2015.08.080
Main files (2)
Article (Published version)
Article (Published version)
Identifiers
- PID : unige:96702
- DOI : 10.1016/j.ijcard.2015.08.080
- PMID : 26386921
ISSN of the journal0167-5273